Figure 3.

Clinical significance of FASN expression in high-grade ovarian serous carcinoma. (a) Comparison of FASN immunointensity scores for 28 pairs of matched primary and recurrent tumors from the same patients. Recurrent tumors exhibit elevated expression when compared to primary specimens from the same patient (P < .0001). (b) FASN staining of the primary and recurrent tumors from two representative patients. (c) Kaplan-Meier curve analysis shows that patients whose tumors exhibit higher FASN immunostaining scores have significantly shorter survival times than those whose tumors show undetectable or very low FASN immunoreactivity (60.4 versus 36.9 months, P < .01).